Get More Information on Recombinant Vaccines Market - Request Sample Report
The Recombinant Vaccines Market Size was valued at USD 12.53 Billion in 2023, and is expected to reach USD 32.83 Billion by 2032, and grow at a CAGR of 11.88%.
The driving force behind the substantial growth of the recombinant vaccine market is the increasing prevalence of infectious diseases on a global scale. As a result, vaccinations have become a highly important practice across the globe. Governmental initiatives also fuel this trend. Specifically, as reported by WHO, over 2.5 million deaths were associated with vaccine-preventable diseases in 2023. In the U.S., the rate of vaccination as reported by the CDC showed a 12 percent increase, or approximately 20.3 million additional vaccinations delivered. The effect was particularly pronounced in the cases of hepatitis B and HPV, which represent contagions addressed by recombinant vaccines.
Additionally, as reflected by ECDC, the European Union saw substantial growth in the rate of immunization, reaching 14 percent in 2023. Specifically, a major driver of the trend was the government-sponsored initiative to increase population access to the HPV vaccines implemented across the union. As a result of the aggregate of these key factors, and their reflection in statistical data, throughout the global context, the recombinant vaccines reflect their universal importance, and the global aspect of their rising dominance is a major cause of the new market changes.
Key Drivers:
The Increasing Incidence of Infectious Diseases Globally, Such as Influenza, Hepatitis, and HPV, Is Driving the Demand for Recombinant Vaccines.
Technological Innovations in Genetic Engineering and Biotechnology are Leading to the Creation of Safer and More Effective Recombinant Vaccines.
Restraints:
The High Cost of Recombinant Vaccines Limit Accessibility in Low-Income Regions is Hindering Market Expansion.
The Stringent Regulatory Environment Poses Challenges to the Growth of the Market.
Opportunity:
The Growing Demand for Vaccines in Emerging Markets Presents Significant Opportunities for the Recombinant Vaccines Market.
The Trend Towards Personalized Medicine is Opening New Avenues in the Creation of Personalized Recombinant Vaccines Tailored to Individual Genetic Profiles.
By Type
In 2023, the subunit vaccines segment was the largest, representing 75% of the share. Subunit vaccines were also the most popular vaccine type from 2017 – 2023 for the same reasons discussed above, in addition to the safety of these vaccines. Subunit vaccines only contain specific antigens of the pathogenic virus, which reduces the likelihood of an adverse reaction. Therefore, subunit vaccines can be safely given to vulnerable populations, such as infants, the elderly, and immunocompromised people. The CDC reported that in 2023, more than 70% of routine annual vaccination schedules made use of subunit vaccines in the United States.
The WHO reports that there was a 15% rise in subunit vaccines distributed worldwide in 2023, which was mainly attributed to international vaccination campaigns in low and middle-income countries and International Vaccination Agency collaborations. Demand for subunit vaccines will continue to rise because they offer a safer alternative to live attenuated vaccines. Although live vaccines have proven to be more effective, they also have a higher risk of side effects, particularly in the case of those who have a weakened immune system.
Need any customization research on Recombinant Vaccines Market - Enquiry Now
By Indication
The vaccine currently contributing to the disease indication segment, which had the highest share of the market in 2023, is HPV with a total percentage of 25% share, and is projected to be the fastest-growing segment. This dominance is owed to the more sales of vaccines across the world as a result of its higher demand and procurement volume. In addition, the market value is projected to increase in the coming years, attributed to the pipeline of candidates for the HPV vaccines. Besides, the HPB vaccine and rotavirus also play a role in the growth of the market since HPV is more prevalent in emerging and underdeveloped states. For example, VAXELIS was approved by the USFDA for MSD and Sanofi to treat different diseases, including hepatitis B. Most states are expected to adopt the policies for the hepatitis B vaccine for babies. It is likely to increase the demand and sales for the hepatitis B vaccine globally.
Despite the lower CAGR and revenue generation, the herpes zoster, meningococcal B, and other vaccine segments are projected to record numerous R&D in the forecast period. This is attributed to the numerous trials currently using recombinant technology and resources. Currently, in a phase 3 clinical trial, GlaxoSmithKline had a pipeline candidate for reducing the risk of herpes zoster among the population. The primary factor that will impact the sales and demand of vaccines is the increasing awareness among individuals regarding the advantages of immunization.
The market for recombinant vaccines was dominated by North America in 2023, with a market share of 39%. The performance was due to the demand for efficient vaccines and R&D investments by major industry players. In addition, R&D is due to the availability of advanced molecular & genetic engineering equipment. The government of North America is amending vaccine immunization programs to cover the entire region. Therefore, the availability of new recombinant vaccines is expected to drive growth in the region.
However, Asia-Pacific is expected to exhibit the greatest growth in the market. The amendment to immunization programs in Asia-Pacific by governments is leading to a rising demand for effective vaccines in the region. Further, the increasing incidence of diseases like human papillomavirus and hepatitis B is driving the criterion for vaccine supply in the Asia-Pacific region.
The key market players are GlaxoSmithKline plc., C.H. Boehringer Sohn AG & Co.KG, Merck & Co., Inc, Sanofi, Pfizer Inc., LG Chem, Dynavax Technologies, Serum Institute of India Pvt. Ltd, Novartis AG, Sinovac Biotech Ltd & other players.
RECENT DEVELOPMENTS
In April 2023, Pfizer Inc. announced the completion of phase III clinical trials and the subsequent approval of a new recombinant pneumococcal vaccine, Prevnar 20™ by the U.S. FDA. The vaccine is an immunization vaccine that is intended for the prevention of diseases that are caused by Streptococcus pneumoniae.
In June 2021, GlaxoSmithKline plc. announced the approval of its new recombinant shingles vaccine, Shingrix™, and launched it into the market.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 12.53 Billion |
| Market Size by 2032 | US$ 32.83 Billion |
| CAGR | CAGR of 11.88% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Type (Subunit and Live Attenuated) •By Route of Administration (Parenteral and Oral) •By Disease Indication (Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | GlaxoSmithKline plc., C.H. Boehringer Sohn AG & Co.KG, Merck & Co., Inc, Sanofi, Pfizer Inc., LG Chem, Dynavax Technologies, Serum Institute of India Pvt. Ltd, Novartis AG, Sinovac Biotech Ltd & other players |
| Key Drivers | •The Increasing Incidence of Infectious Diseases Globally, Such as Influenza, Hepatitis, and HPV, Is Driving the Demand for Recombinant Vaccines. •Technological Innovations in Genetic Engineering and Biotechnology are Leading to the Creation of Safer and More Effective Recombinant Vaccines. |
| RESTRAINTS | •The High Cost of Recombinant Vaccines Limit Accessibility in Low-Income Regions is Hindering Market Expansion. •The Stringent Regulatory Environment Poses Challenges to the Growth of the Market. |
Ans: The Recombinant Vaccines Market is to grow at a CAGR of 11.88% Over the Forecast Period 2024-2032.
Ans. The Recombinant Vaccines Market size was valued at USD 12.53 Billion in 2023.
Ans. Subunit Recombinant Vaccines are the market's leading type segment.
Ans. High vaccination costs and the significant dangers associated with attenuated vaccines are two reasons that may stymie the worldwide recombinant vaccines industry.
Ans. The recombinant vaccines market is highly concentrated, with the top manufacturers accounting for 80% of the overall share.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Indication and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Indication Benchmarking
6.3.1 Indication specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Indication launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Recombinant Vaccines Market Segmentation, by Indication
7.1 Chapter Overview
7.2 Human Papillomavirus (HPV)
7.2.1 Human Papillomavirus (HPV) Market Trends Analysis (2020-2032)
7.2.2 Human Papillomavirus (HPV) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Hepatitis B
7.3.1 Hepatitis B Market Trends Analysis (2020-2032)
7.3.2 Hepatitis B Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Rotavirus
7.4.1 Rotavirus Market Trends Analysis (2020-2032)
7.4.2 Rotavirus Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Herpes Zoster
7.5.1 Herpes Zoster Market Trends Analysis (2020-2032)
7.5.2 Herpes Zoster Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Meningococcal B
7.6.1 Meningococcal B Major/SCD Market Trends Analysis (2020-2032)
7.6.2 Meningococcal B Major/SCD Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Others
7.7.1 Others Market Trends Analysis (2020-2032)
7.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Recombinant Vaccines Market Segmentation, by Route of Administration
8.1 Chapter Overview
8.2 Parenteral
8.2.1 Parenteral Market Trends Analysis (2020-2032)
8.2.2 Parenteral Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Oral
8.3.1 Oral Market Trends Analysis (2020-2032)
8.3.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Recombinant Vaccines Market Segmentation, by Type
9.1 Chapter Overview
9.2 Subunit
9.2.1 Subunit Market Trends Analysis (2020-2032)
9.2.2 Subunit Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Live Attenuated
9.3.1 Live Attenuated Market Trends Analysis (2020-2032)
9.3.2 Live Attenuated Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.4 North America Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.5 North America Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.6.2 USA Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.6.3 USA Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.7.2 Canada Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.7.3 Canada Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.2.8.2 Mexico Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.8.3 Mexico Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.6.2 Poland Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.6.3 Poland Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.7.2 Romania Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.7.3 Romania Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.4 Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.5 Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.6.2 Germany Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.6.3 Germany Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.7.2 France Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.7.3 France Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.8.2 UK Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.8.3 UK Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.9.2 Italy Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.9.3 Italy Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.10.2 Spain Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.10.3 Spain Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.13.2 Austria Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.13.3 Austria Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.4 Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.5 Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.6.2 China Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.6.3 China Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.7.2 India Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.7.3 India Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.8.2 Japan Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.8.3 Japan Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.9.2 South Korea Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.9.3 South Korea Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.10.2 Vietnam Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.10.3 Vietnam Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.11.2 Singapore Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.11.3 Singapore Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.12.2 Australia Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.12.3 Australia Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.4 Middle East Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.5 Middle East Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.6.2 UAE Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.6.3 UAE Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.4 Africa Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.5 Africa Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Recombinant Vaccines Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.4 Latin America Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.5 Latin America Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.6.2 Brazil Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.6.3 Brazil Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.7.2 Argentina Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.7.3 Argentina Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.8.2 Colombia Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.8.3 Colombia Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Recombinant Vaccines Market Estimates and Forecasts, by Indication (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Recombinant Vaccines Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Recombinant Vaccines Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
11. Company Profiles
11.1 GlaxoSmithKline plc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Indication s/ Indication s Offered
11.1.4 SWOT Analysis
11.2 C.H. Boehringer Sohn AG & Co.KG
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Indication s/ Indication s Offered
11.2.4 SWOT Analysis
11.3 F. Merck & Co., Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Indication s/ Indication s Offered
11.3.4 SWOT Analysis
11.4 Sanofi
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Indication s/ Indication s Offered
11.4.4 SWOT Analysis
11.5 Pfizer Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Indication s/ Indication s Offered
11.5.4 SWOT Analysis
11.6 LG Chem
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Indication s/ Indication s Offered
11.6.4 SWOT Analysis
11.7 Dynavax Technologies
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Indication s/ Indication s Offered
11.7.4 SWOT Analysis
11.8 Serum Institute of India Pvt. Ltd
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Indication s/ Indication s Offered
11.8.4 SWOT Analysis
11.9 Novartis AG
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Indication s/ Indication s Offered
11.9.4 SWOT Analysis
11.10 Sinovac Biotech Ltd.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Indication s/ Indication s Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type
Subunit
Live Attenuated
By Route of Administration
Parenteral
Oral
By Indication
Human Papillomavirus (HPV)
Hepatitis B
Rotavirus
Herpes Zoster
Meningococcal B
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Medical Imaging Workstations Market Size was valued at USD 5.49 billion in 2022, and is expected to reach USD 10.02 billion by 2030 and grow at a CAGR of 7.8% over the forecast period 2023-2030.
The Skin Cancer Treatment Market Size was valued at USD 10.98 Billion in 2023 and is expected to reach USD 20.74 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Protein Engineering Market size was estimated USD 2.59 billion in 2023 and is expected to reach USD 10.04 billion by 2032 at a CAGR of 16.25% during the forecast period of 2024-2032.
The Lymphoma Treatment Market size was valued at USD 9.08 Billion in 2023 & is estimated to reach USD 19.09 Billion by 2032 with a growing CAGR of 8.61% between 2024 and 2032.
The Functional Endoscopic Sinus Surgery Market Size was valued at USD 1.01 Billion in 2023, and is expected to reach USD 1.91 Billion by 2032, and grow at a CAGR of 7.66% over the Forecast Period of 2024-2032.
The Medical Collagen Market Size was valued at USD 708.98 Million in 2023, and will reach USD 1138.57 Mn by 2031, and grow at a CAGR of 6.1% by 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
